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Introduction
For patients with non-small cell lung cancer (NSCLC) and 
no systemic metastasis, mediastinal staging is very important 
as it provides accurate information on the extent of the 
disease, it guides the choice of treatment and determines 
the patient’s prognosis.
In 2007, the European Society of Thoracic Surgeons (ESTS) 
published an algorithm on preoperative mediastinal staging 
based on the current available literature (1). These guidelines 
integrated imaging, endoscopic and surgical techniques. 
They were widely used and have been prospectively validated. 
Their negative predictive value is 0.94 (2).
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New insights on the importance of restaging and 
techniques for mediastinal restaging have become available. 
Therefore, the ESTS Council approved the initiative by the 
working group to revise and update the previous guidelines 
on mediastinal staging.
Methodology
There were several meetings of the working group. The 
project was discussed in the Council at the ESTS meeting 
in Essen (June 2012). There were several meetings 
(Essen, Zürich, Brussels and Birmingham) where the 
participants presented their experience and discussed the 
relevant literature published since 2007. Initial findings 
were presented and discussed at the ESTS meeting in 
Birmingham (May 2013). The final paper was put on the 
website for discussion by all ESTS members. Their remarks 
were discussed and included in the final manuscript.
For recommendations, a level of evidence and grading 
of recommendation is given. This was adapted from the 
Infectious Disease Society of American-United States 
Public Health Service Grading System (Table 1) (3).
It is evident that both in primary staging and restaging, 
not every technique is available in every centre. Therefore, 
staging and restaging techniques can differ between 
different countries and centres.
Rationale for preoperative mediastinal nodal staging
The current guidelines for treatment of lung cancer are 
determined by the clinical status of the mediastinal nodes. 
The aim of mediastinal staging is to exclude with the 
highest certainty and the lowest morbidity patients with 
mediastinal nodal disease since these patients will not 
benefit from upfront surgery (4,5).
There is controversy regarding the best treatment of N2 
disease because of the heterogeneity of nodal involvement. 
Also patient and tumour characteristics and extent of 
resection plays a role in the selection of treatment modality 
for these patients.
There is a subgroup of patients with pretreatment 
histologically proven N2 disease who are candidate 
for surgical multimodality treatment. These patients 
are treated with induction chemotherapy or induction 
chemoradiotherapy. In case of downstaging of the mediastinal 
lymph nodes or major response in those lymph nodes and 
in the tumour, resection with systematic nodal dissection 
can be performed with acceptable morbidity and mortality 
and rewarding 5-year survival. There are several prognostic 
indicators, some of them are related to the primary tumour 
and others are related to the extent of nodal disease. To 
include patients for surgical multimodality treatment, the 
disease should be initially technically resectable. Excluded 
for surgical multimodality are patients with unresectable 
disease such as extracapsular disease (can be clearly visualized 
by mediastinoscopy), or bulky N2 disease based on CT. Fit 
patients with extracapsular disease and/or bulky N2 disease 
should be treated with definitive chemoradiotherapy.
Bulky N2 disease is not well defined but it correlates 
with the radiographic group A, as described in the American 
College of Chest Physicians (ACCP) Evidence-based 
Clinical Practice Guidelines (6). This group is defined as 
Table 1 Level of evidence and grading of recommendation (3)
Level Type of evidence
I Evidence from at least one large randomized control trial of good methodological quality (low potential for bias) or  
meta-analyses of well-conducted randomized trials without heterogeneity
II Small randomized trials or large randomized trials with a suspicion of bias (lower methodological quality) or meta-analyses 
of such trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case-control studies
V Studies without control group, case reports, experts opinions
A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs), optional
D Moderate evidence against efficacy or for adverse outcome, generally not recommended
E Strong evidence against efficacy or for adverse outcome, never recommended
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mediastinal infiltration where the discrete lymph nodes 
cannot be distinguished or measured. Bulky is not strictly 
related to the size of the lymph nodes, but it is considered 
by this committee that lymph nodes larger than 25 mm 
short axis will also be defined as bulky disease (level V). 
Bulky disease can be restricted to a single station but usually 
represents multistation or multiple zonal involvement. Since 
this paper deals with preoperative lymph node staging, 
techniques to obtain histology in bulky mediastinal nodal 
disease are beyond the scope of this article.
Preoperative mediastinal lymph node staging
Several techniques are available and their use depends on 
local availability and local expertise.
These techniques include: 
(I) Imaging techniques; 
(II) Endoscopic techniques; 
(III) Surgical techniques. 
Although we should aim for the test with the highest 
sensitivity and NPV, the working group considers a rate 
of unforeseen pN2 disease of 10% as acceptable. After 
thorough mediastinal staging this unforeseen pN2 is mostly 
single station resectable nodal disease.
Imaging techniques
Chest CT-scan
Computed tomography remains important in lung cancer 
imaging. However, due to its low sensitivity (55%) and 
specificity (81%) it is impossible to solely rely on CT-
scan (6). CT-scan may help us in selecting the appropriate 
procedure for tissue sampling due to the anatomical images 
it provides.
PET-CT scan
The addition of PET to CT results in more accurate lymph 
node staging than CT alone with an overall sensitivity of 
80-90% and specificity of 85-95%. PET-CT has a high 
NPV for detecting mediastinal nodal disease in peripherally 
located NSCLC. Exceptions include:
(I) Suspected N1 nodes;
(II) Tumour >3 cm;
(III) Centrally located tumour without suspected nodes 
on CT or PET scan. 
In a study from Japan (7), 30% of 143 patients with N1 
disease on CT-scan (lymph node short axis >1 cm) were 
found to have pathologic N2-N3.
A recent meta-analysis (8) has shown that the negative 
predictive value of PET-CT for tumours ≤3 cm was 94% 
(649 patients) compared to 89% for tumours >3 cm (130 
patients) staged as T2 (6th edition of TNM). This finding 
was confirmed in a recent prospective study from Spain (9). 
For peripheral tumours ≤3 cm the negative predictive value 
of PET-CT was 92% while it was 85% for tumours >3 cm. 
Based on these studies, we now recommend that for 
peripheral tumours (outer third of the lung) ≤3 cm without 
enlarged (hilar and/or mediastinal) lymph nodes on CT 
and with PET-negative nodes, further mediastinal staging 
can be omitted. There was a substantial difference in rate 
of mediastinal nodal disease between adenocarcinoma and 
other tumour histology (risk ratio 2.72). Also high FDG 
uptake in the primary lesion was associated with greater 
risk of occult nodal metastasis. For tumours >3 cm (mainly 
adenocarcinoma with high FDG uptake) further mediastinal 
staging techniques providing histology should be considered.
Lee et al. (10) examined the prevalence of pathologic N2 
disease in patients with clinical stage I NSCLC (6th edition 
of TNM version) with negative mediastinum on PET and 
CT. In 2.9% of peripheral tumours (outer third of lung) N2 
disease was found, while the prevalence of N2 disease was 
21.6% in central tumours.
Diffusion-weighted magnetic resonance imaging
Advances in MRI technology have allowed acquisition of 
diffusion-weighted MRI (DWI), which provides excellent 
tissue contrast because of the difference in the diffusion 
of water molecules among tissues. The technique yields 
qualitative and quantitative information that reflects changes 
at a cellular level and provides unique insights about tumour 
cellularity and the integrity of cell membranes. In a recent 
meta-analysis (11) the accuracy of DWI and 18F-FDG 
PET/CT was evaluated. The pooled sensitivity for DWI 
was 0.95 (95% CI, 0.85-0.98) and significantly better than 
for FDG-PET/CT 0.89 (89% CI, 0.85-0.91). However, 
at this moment there are no large prospective studies 
comparing the value of DWI and FDG-PET and it is too 
early to determine the true value of DWI in nodal staging 
in patients with NSCLC.
Endoscopic techniques
Conventional TBNA
Although the conventional TBNA technique has been 
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available for almost three decades, its use in routine clinical 
practice has only been adopted by a minority (10-15%) of 
pulmonologists for mediastinal nodal staging of patients 
with potentially resectable stage I-III lung cancer. Major 
reasons for its underuse are its dependency on nodal size 
(>15-20 mm short axis on CT scan) and operator skills. 
Meta-analyses reported a sensitivity of 78% and a false 
negative rate of 28% for conventional TBNA in clinical 
N2 disease with high disease prevalence of 81% (12,13). A 
conventional blind TBNA is useful if it leads to proof of N3 
disease, but too often does not exclude N3 disease in cases 
of proven N2 disease.
Endoscopic ultrasonography: EUS-FNA and EBUS-TBNA
Practical aspects
Although E(B)US-TBNA is performed in some centers 
under general anesthesia, EBUS and EUS are more often 
performed in an outpatient setting under local anesthesia 
with moderate sedation.
EBUS is able to visualise superior and inferior 
mediastinal LNs at stations 2R/2L, 4R/4L and 7, as well as 
hilar LNs at stations 10, 11, and even 12, as described on 
the new LN map (14). EUS particularly visualises superior 
mediastinal lymph nodes in station 4L, and inferior 
mediastinal nodes in stations 7, 8 and 9, as described on the 
new LN map (Rusch 2009). Thus, EUS-FNA complements 
other techniques, as several of these LNs (stations 8 and 9) 
are not accessible by EBUS-TBNA or mediastinoscopy. 
Although some expert centres considered EUS-FNA of 
lymph nodes in stations 5 or 6, currently available data are 
limited and therefore we do not recommend routine use of 
this procedure for this indication (15).
It is possible to visualize and sample lymph nodes with a 
short axis of >5 mm and the optimal number of aspirations 
per station has been reported to be three (16). When 
mediastinal nodal staging is required, systematic nodal 
sampling is feasible by endosonography. Indeed, several 
endosonography series have shown a mean or median 
number of sampled mediastinal nodal stations of 3 to 4 per 
patient (17-22). Nodal stations 4R, 4L, and 7 should always 
be sought during the endosonographic examination and 
described in the medical report. In addition the largest node 
measuring >5 mm on ultrasonography within each of these 
stations as well as FDG avid nodes within each of these 
nodal stations should be sampled for pathological analysis. 
On indication nodal station 10R and 10L can be biopsied. 
To avoid contamination while using one single needle for 
an EBUS or EUS procedure, the order of nodal sampling 
should begin at the level of N3 nodes followed by N2 nodes 
before ending with N1 nodes.
Performance characteristics
Several meta-analyses on EUS-FNA alone, EBUS-TBNA 
alone, and combined EUS+EBUS reported a pooled 
sensitivity of 83% to 94% for mediastinal staging of lung 
cancer (Table 2) (23-27). Only one randomized controlled 
trial (Aster trial, 17) has been performed, comparing the two 
staging strategies proposed in the ESTS 2007 guidelines 
(either mediastinoscopy, or alternatively endosonography 
followed by mediastinoscopy) (1). There was no difference in 
sensitivity or NPV when mediastinoscpy was compared with 
endoscopic staging. However, the staging strategy starting 
with combined endosonography and if negative combining it 
with surgical staging has proven to detect significantly more 
mediastinal nodal N2/3 disease compared to mediastinoscopy 
alone (17). Another consequence is that the implementation of 
endosonography for baseline mediastinal nodal staging clearly 
reduces the need for mediastinoscopy (28). On the other 
hand, the negative likelihood ratio reported by three of the 
Table 2 Published meta-analyses on endobronchial and oesophageal endosonography with fine needle aspiration for mediastinal nodal 
staging of lung cancer
Author Year Modality Pts (N) Pooled sens % (95% CI) Pooled spec % (95% CI) NLR
Micames, et al. (23) 2007 EUS 1,201 83 [78-87] 97 [96-98] –
Gu, et al. (24) 2009 EBUS 1,298 93 [91-94] 100 [99-100] –
Adams, et al. (25) 2009 EBUS 817 88 [79-94] 100 [92-100] 0.12
Chandra, et al. (26) 2012 EBUS 1,658* 92 [90-93] 100 [97-100] 0.13
Zhang, et al. (27) 2013 EUS + EBUS 823 86 [82-90] 100 [99-100] 0.15
N, number; CI, confidence intervals; EUS, esophageal endosonograph; EBUS, endobronchial endosonography; Pts, patients; 
Sens, sensitivity; Spec, specificity; NLR, negative likelihood ratio; *, some small series also included sarcoidosis.
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meta-analyses is 0.13 to 0.15 (Table 2) (25-27). This implies 
that the probability of having mediastinal nodal involvement 
for any individual patient with a negative endosonography 
result is 13-15%. This probability based on endosonography 
alone is in our opinion not low enough to directly proceed to 
a surgical resection. Therefore in the routine practice we still 
recommend a preoperative surgical staging procedure (i.e., 
VAM) in case of a negative endosonography. However, there 
is evidence coming from prospective studies performed in 
experienced endosonography centres, that mediastinoscopy 
may not improve sensitivity after a well-performed negative 
endosonography with needle aspiration of at least three 
mediastinal nodal stations in patients with low (<35%) 
prevalence of mediastinal disease (18,29,30). EBUS-TBNA 
and EUS-FNA are safe procedures with reported minor 
complications in <1% of cases (23,24,31). With the rapidly 
increasing number of procedures, occasional reports of 
moderate to severe complications have been published, such 
as pneumothorax requiring chest tube drainage, infection 
of bronchogenic cyst, empyema, lung and/or mediastinal 
abscess, and haemopneumomediastinum are published. So far, 
only one death has been reported related to an EBUS-TBNA 
procedure (32).
Surgical staging techniques
Cervical mediastinoscopy
Cervical mediastinoscopy through a pretracheal suprasternal 
incision was introduced by Carlens in 1959 and further 
popularized by Pearson in North America. It allows a 
full mapping of the ipsilateral and contralateral superior 
mediastinal lymph nodes. Cervical mediastinoscopy is 
performed under general anaesthesia and can be safely done 
as an outpatient procedure. For many years it was the gold 
standard for invasive staging of patients with potentially 
operable lung cancer. Since 1995, use of video techniques has 
been introduced leading to video-assisted mediastinoscopy 
(VAM). VAM clearly improved visualization and teaching (33) 
since both the trainer and the trainee can share the magnified 
image on the monitor. For more details on the technique of 
cervical mediastinoscopy, we refer to a recent publication on 
this topic (34).
There are only retrospective studies comparing the 
safety and accuracy of conventional mediastinoscopy with 
VAM. Although some authors (35-37) found an increase in 
the number of LN or LN stations biopsied, no difference 
in sensitivity or NPV was found. In some of these studies 
a reduction in the complication rate (mainly of recurrent 
nerve palsy) was observed. Very recently (38), a best 
evidence topic has been published on the safety and accuracy 
of VAM compared to conventional mediastinoscopy 
(Table 3). The authors analysed 108 papers published 
between 1989 and 2011. There were 5,156 conventional 
mediastinoscopies and 956 VAMs. Both procedures are safe 
with no mortality in that time frame and a low morbidity. 
Although by VAM more lymph node stations are sampled, 
the negative predictive value and accuracy were identical.
Although the video-mediastinoscope is not strictly 
necessary to achieve a thorough, clinically acceptable 
mediastinoscopy, it has many advantages over the 
conventional one: larger and clearer images, the possibility 
to simultaneously share the procedure with trainees and 
all the personnel in the operative theatre, the possibility 
to record the operation for future educational uses and 
discussion, and the possibility to improve its teaching 
without compromising the safety or accuracy of the 
procedure. Moreover it allows bimanual dissection with 
possibilities to perform nodal dissection and removal rather 
than sampling or biopsy. This is especially important 
and technically feasible for the subcarinal LN station. 
After removal of station 7 LNs, the oesophagus can be 
Table 3 Overall comparison VAM vs. CM (Studies 1989-2011)
VAM (n=956) CM (n=5,156) P value
Mortality 0 0
Morbidity 0.83-2.9% 0-5.3% NS
No. of LN biopsied 6-8.5 5-7.13 NS
No. LN stations sampled 1.9-3.6 2.6-2.98 NS
Accuracy 87.9-98.9% 83.8-97.2% NS
NPV 83.0-98.6% 81.0-98.7% NS
VAM, videomediastinoscopy; CM, conventional mediastinoscopy; NPV, negative predictive value. Adapted from Zakkar et al. (38).
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clearly visualized. The ESTS working group recommends 
performing VAM.
Video-assisted thoracoscopic surgery (VATS)
Although VATS can reach almost every mediastinal 
lymph node station, it is more invasive than cervical 
mediastinoscopy (it needs double lumen intubatio), it 
is limited by pleural adhesions, and it can only evaluate 
ipsilateral nodal disease. For the para-aortic lymph nodes 
(station 6) and the subaortic lymph nodes (station 5), left 
VATS is a surgical technique that allows obtaining large 
tissue samples. It is indicated when enlarged PET positive 
lymph nodes are visualized at level 5 or 6. These lymph node 
stations cannot be biopsied by routine mediastinoscopy, 
E(B)US-FNA. An alternative to VATS is the left anterior 
mediastinotomy. In some experienced centres, extended 
mediastinoscopy from the mediastinoscopy incision is 
performed for these lymph node stations and it gives good 
negative predictive values: 0.89-0.97 (34).
Video-assisted mediastinoscopic lymphadenectomy (VAMLA) 
transcervical extended mediastinal lymphadenectomy 
(TEMLA)
During the last decade, two new invasive staging techniques 
representing more radical methods of mediastinal 
explorat ion have  been introduced:  VAMLA (39) 
and TEMLA (40). These two techniques aim for a 
complete removal of all the mediastinal nodes with the 
surrounding adipose tissue to improve the accuracy of 
staging. VAMLA is completely performed with the use of 
the videomediastinoscope whilst TEMLA uses a 5-8 cm 
collar incision in the neck and elevates the sternum with 
a hook. The dissection is performed in an open way and 
with the use of the videomediastinoscope. By VAMLA, 
the lymph nodes which are usually accessible through 
mediastinoscopy, are removed. By TEMLA, more lymph 
node stations are accessible such as the prevascular, the para-
aortic, the subaortic and the para-oesophageal lymph node 
stations. The negative predictive value is very high and 
approaches 98.7% for TEMLA. Although there is no doubt 
that the accuracy of mediastinal staging increases when 
lymphadenectomy is performed compared to nodal biopsy, 
these techniques have a higher morbidity and mortality. The 
complications after VAMLA and TEMLA are well recorded 
and are probably more studied in detail than after CM or 
VAM. These procedures are performed in very experienced 
centres. For VAMLA mainly problems with recurrent nerve 
palsy and important scarring with an impact on subsequent 
resection are reported (39,41-44). The published data for 
TEMLA are mainly from one very experienced centre and 
there are concerns on morbidity and mortality.
For TEMLA and VAMLA we conclude that currently 
available data regarding its use are limited and, therefore, 
we do not recommend its use except of clinical trials. We 
encourage other centres to publish their data with these 
new staging techniques.
The algorithm for preoperative mediastinal staging is 
shown in Figure 1. For NSCLC, both for mediastinal as for 
distant staging, PET or PET-CT is indicated.
● Direct surgery can be performed if all of these three 
criteria apply: no suspect lymph node detected by 
CT or PET, a tumor ≤3 cm (stage IA), located in the 
outer third of the lung (level IIA).
● In case of enlarged mediastinal lymph nodes on CT 
or PET-positive lymph nodes, tissue confirmation 
is indicated. In this case, endosonography (EBUS/
EUS) with fine needle aspiration is the first choice 
(when available) since it is minimally invasive and has 
a high sensitivity to rule in mediastinal nodal disease 
(level IA). If negative, video-assisted mediastinoscopy 
is indicated (level IB). The combined use of 
endoscopic staging and surgical staging results in the 
highest accuracy.
For patients with a left upper lobe tumour, surgical 
staging of the aorto-pulmonary window nodes (if enlarged 
on CT and/or PET-CT-positive) can be performed (by 
anterior mediastinotomy, VATS or extended cervical 
mediastinoscopy) if involvement changes treatment strategy 
(level V).
● Invasive staging by E(B)US/mediastinoscopy is 
indicated if at least one of these criteria apply: central 
lesion, suspect N1 nodes (level IIB). In case of tumors 
>3 cm (mainly in adenocarcinoma with high FDG 
uptake) the negative predictive value for mediastinal 
nodal disease is <90% and invasive staging may 
be considered (level IIB). Although a high FDG 
update in the primary tumor is a predictor of N2 
disease, the ideal cutoff of SUV value has not yet 
been determined above which invasive mediastinal 
nodal staging is required. In addition, the SUV 
measurement is not yet standardized from one center 
to another and therefore a visual interpretation of 
the FDG uptake on PET is to be preferred (Dooms 
2010). In all of the above-mentioned cases there is 
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the choice between VAM with biopsy or lymph node 
dissection or endoscopic staging by EBUS/EUS 
with fine needle aspiration. The choice depends on 
local expertise to adhere to minimal requirements for 
staging (level V). If video-assisted mediastinoscopy 
is negative, these patients can undergo surgical 
treatment. They also can undergo surgical treatment 
after negative EBUS/EUS if the number of nodes 
explored and the number of needle passes in each 
node meet the established requirements. Otherwise, 
surgical exploration is recommended after negative 
EBUS/EUS.
● If only CT is available, we refer to the algorithm of 
the 2007 edition of the ESTS guidelines (De Leyn 
2007).
We conclude that optimal mediastinal lymph node 
staging is a truly multidisciplinary process, with a variety of 
possible techniques, to be performed by experienced hands.
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